SYRS
Syros Pharmaceuticals, Inc.
Set alert
- YTD
- +14.29%
- 1 year
- 0.00%
- Open
- 0.0005
- Prev close
- 0.0004
- Mkt cap
- 10.73K
- Vol
- 904
- Avg vol
- 12.52K
- EPS
- -6.14
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0005
- High
- 0.0005
- Forward P/E
- -0.08
- Beta
- 1.59
- Short ratio
- 0.10
- Inst. own
- 75.59%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.20
- 200-d avg
- 3.65
- 1y target
- 1.00
Key statistics
- Market cap
- 5.47M
- Enterprise value
- 7.32M
- Trailing P/E
- 0.00
- Forward P/E
- -0.08
- PEG ratio
- 0.00
- Price / sales
- 14.17
- Price / book
- 0.00
- EPS (TTM)
- -3.07
- Beta
- 1.59
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 386.00K
- Revenue growth
- 0.00%
- Free cash flow
- -57.94M
- Total cash
- 58.27M
- Total debt
- 60.23M
- Return on equity
- -776.96%
- Shares outstanding
- 26.83M
- Short % of float
- 9.06%
- 50-day average
- 1.20
- 200-day average
- 3.65
Analyst view
Consensus: none
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.70667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | -0.76 | -0.68 | +0.08 | +10.53% |
| Jul 31, 2024 | Jun 1, 2024 | -0.79 | -0.70 | +0.09 | +11.39% |
| May 14, 2024 | Mar 1, 2024 | -0.89 | -0.79 | +0.10 | +11.24% |
| Mar 27, 2024 | Dec 1, 2023 | -1.23 | -1.19 | +0.04 | +3.25% |
| Nov 14, 2023 | Sep 1, 2023 | -1.12 | -1.35 | -0.23 | -20.54% |
| Aug 8, 2023 | Jun 1, 2023 | -1.11 | -1.30 | -0.19 | -17.12% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | TD Cowen | down | Buy | Hold |
| Nov 13, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 13, 2024 | JMP Securities | down | Market Outperform | Market Perform |
| Nov 13, 2024 | Brookline Capital | down | Buy | Hold |
| Nov 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | Piper Sandler | reit | Overweight | Overweight |
About Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- syros.com
News
- Critical Analysis: Syros Pharmaceuticals (NASDAQ:SYRS) & ADVANZ PHARMA (OTCMKTS:CXRXF)
- Cyclacel Pharmaceuticals (NASDAQ:BGMS) vs. Syros Pharmaceuticals (NASDAQ:SYRS) Head to Head Analysis
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- US Stocks Likely To Open Higher As Wall Street Watches Trump Tariff Talks: 'March, April, May Tend To Be Solid Months In Post-Election Years,' Says Expert
- Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
- Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
Your note
Sign in to keep a note on SYRS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | Conversion of Exercise of derivative security | Sep 15, 2024 | 9,333 |
| CHEE CONLEY | Chief Executive Officer | Sale | Nov 17, 2024 | 0 |
| FANUCCI MARSHA H | Director | Stock Award(Grant) | Jun 4, 2024 | 16,000 |
| HAAS JASON | Chief Financial Officer | Sale | Nov 17, 2024 | 0 |
| QUIRK GERALD E. | Officer | Sale | Nov 18, 2024 | 0 |
| ROTH DAVID A M.D. | Officer | Sale | Nov 17, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 10.25% | 2,750,151 | 560.75K | Sep 29, 2024 |
| Siren, L.L.C. | 9.64% | 2,587,372 | 527.57K | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 7.72% | 2,071,914 | 422.46K | Sep 29, 2024 |
| Samsara BioCapital, LLC | 6.66% | 1,786,427 | 364.25K | Sep 29, 2024 |
| Point72 Asset Management, L.P. | 5.49% | 1,471,771 | 300.09K | Sep 29, 2024 |
| Flagship Pioneering Inc. | 4.82% | 1,293,849 | 263.81K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.44% | 654,183 | 133.39K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.96% | 257,635 | 52.53K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 100,122 | 20.41K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.21% | 56,602 | 11.54K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.19% | 50,670 | 10.33K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 39,831 | 8.12K | Oct 30, 2024 |